Seeking Alpha

Seeking Alpha Portfolio App for iPad

This Market Current was sent to 766 people who get email alerts on ALNY.

Get email alerts on ALNY »

Market Currents

Alnylam Pharmaceuticals (ALNY) is in discussions with "more than one" potential partner to help...

Friday, July 20, 2012, 6:24 AM ET
Alnylam Pharmaceuticals (ALNY) is in discussions with "more than one" potential partner to help it carry out Phase II and Phase III studies of its ALN-PCS treatment for high cholestoral, CEO John Maraganore says, although he declines to name names.

This Market Current was sent to 766 people who get email alerts on ALNY.

Get email alerts on ALNY »

Share this Market Current

Short URL:

Other date

DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles

Medtronic's Defibrillator Sales Show A Pulse With Encouraging Results
7:21 PM • Trefis
Bull of the Day: Santarus
6:03 PM • Zacks Investment Research
The Retire Young Portfolio: Time To Add A High-Growth Medicine Company
4:10 PM • Jacob Steinberg
Regeneron Shareholders Watching Optina Trial Closely
3:56 PM • Tom Welch
Sequenom: Plenty Of Room To Run
3:54 PM • Ravi Jain
Rockwell Steadies Itself For A Phase III Run-Up
3:09 PM • Sam Quirke
Ariad's Cancer Drug Iclusig Extends The Gleevec Magic
1:20 PM • Peter Geschek
Why Momenta Offers A Unique Opportunity In The Pharmaceutical Industry
12:56 PM • Jon Crowley
These 2 Patents Could Mean Everything Or Nothing
11:29 AM • Quoth the Raven
Nanospheres High Margin Pathogen Identification System Shows Promise
9:45 AM • Healthcare Specialist
Dendreon Analysts Getting Very Skeptical
8:49 AM • Bill Maurer
Merck's Novel Immunotherapy Drug Receives 'Breakthrough Therapy Designation'
8:34 AM • The Swiss Trader
The 'New' Celsion Could Be Worth $4 A Share
8:28 AM • Quoth the Raven
Neuralstem Phase I Results Encourage Market, Stimulate Buying
7:33 AM • Brian L. Wilson
Prolor Biotech Buyout: Is The Opko Bear Case Now Dead?
6:10 AM • Daniel Lauchheimer

More Latest Articles »